Generic placeholder image

Current Medicinal Chemistry


ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Bone Target Radiotracers for Palliative Therapy of Bone Metastases

Author(s): K. Ogawa and K. Washiyama

Volume 19, Issue 20, 2012

Page: [3290 - 3300] Pages: 11

DOI: 10.2174/092986712801215865

Price: $65


The skeleton is one of the most common organs affected by metastatic cancer, and bone metastases often cause severe pain, which significantly affects quality of life. Internal radiotherapy using specifically localized bone-seeking radiopharmaceuticals has proven to be an effective alternative and shows fewer side effects than those associated with other forms of treatment. In this review article, we highlight not only radiopharmaceuticals, which have been approved for the palliation of bone metastases but also boneseeking radiolabeled compounds under investigation in basic research. Specifically, we review the efficacy and prospects of phosphorus- 32, strontium-89 chloride, samarium-153-EDTMP, rhenium-186/188-HEDP, rhenium-186/188-complex conjugated bisphosphonate compounds, yttrium-90-DOTA conjugated bisphosphonate, rhenium-186/188-DMSA, radium-223 chloride, thorium-227-EDTMP, thorium-227-DOTMP, and lead/bismuth-212-DOTMP.

Keywords: Bone metastases, pain, palliation, bone-seeking radiopharmaceuticals, metastatic cancer, radiotherapy, boneseeking radiolabeled compounds, conjugated bisphosphonate, radium-223 chloride

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy